Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current

News

Wedbush Upgrades AnaptysBio to Outperform

Author: Benzinga Newsdesk | March 12, 2024 07:11am
Wedbush analyst David Nierengarten upgrades AnaptysBio (NASDAQ:ANAB) from Neutral to Outperform.

Posted In: ANAB